4.76
-0.12(-2.46%)
Currency In USD
| Previous Close | 4.88 |
| Open | 5.05 |
| Day High | 5.4 |
| Day Low | 4.49 |
| 52-Week High | 5.4 |
| 52-Week Low | 1.05 |
| Volume | 18.09M |
| Average Volume | 5.54M |
| Market Cap | 1.13B |
| PE | -14 |
| EPS | -0.34 |
| Moving Average 50 Days | 3.02 |
| Moving Average 200 Days | 2.25 |
| Change | -0.12 |
If you invested $1000 in Taysha Gene Therapies, Inc. (TSHA) since IPO date, it would be worth $197.84 as of October 04, 2025 at a share price of $4.76. Whereas If you bought $1000 worth of Taysha Gene Therapies, Inc. (TSHA) shares 3 years ago, it would be worth $2,288.46 as of October 04, 2025 at a share price of $4.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome
GlobeNewswire Inc.
Oct 02, 2025 12:00 PM GMT
Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA alignment on REVEAL pivotal trial protocol and SA
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
GlobeNewswire Inc.
Aug 05, 2025 8:05 PM GMT
DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic disease
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
GlobeNewswire Inc.
Jun 03, 2025 9:17 PM GMT
Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones supporting